Literature DB >> 10515664

Replicating Huntington's disease phenotype in experimental animals.

E Brouillet1, F Condé, M F Beal, P Hantraye.   

Abstract

Huntington's disease (HD) is an inherited, autosomal dominant, neurodegenerative disorder characterized by involuntary choreiform movements, cognitive decline and a progressive neuronal degeneration primarily affecting the striatum. There is at present no effective therapy against this disorder. The gene responsible for the disease (IT15) has been cloned and the molecular defect identified as an expanded polyglutamine tract in the N-terminal region of a protein of unknown function, named huntingtin (The Huntington's Disease Collaborative Research Group, 1993. Cell 72, 971-983). An intense, search for the cell pathology attached to this molecular defect is currently under way [see Sharp and Ross (1996, Neurobiol. Dis. 3, 3-15) for review]. Huntingtin interacts with a number of proteins, some of which have well identified functions, and it has thus been suggested that alterations in glycolysis, vesicle trafficking or apoptosis play a role in the physiopathology of HD. On the other hand data derived from positron emission tomography (PET), magnetic resonance spectroscopy and post-mortem biochemical evidence for a defect in succinate oxidation have suggested the implication of a primary impairment of mitochondrial energy metabolism. All these hypotheses are not necessarily to be opposed and recent findings indicate that the HD mutation could possibly directly alter mitochondrial functions which would in turn activate apoptotic pathways. To test this mitochondrial hypothesis, we studied the effects in rodents and non-human primates of a chronic blockade of succinate oxidation by systemic administration of the mitochondrial toxin 3-nitropropionic acid (3NP). Extensive behavioural and neuropathological evaluations showed that a partial but prolonged energy impairment induced by 3NP is sufficient to replicate most of the clinical and pathophysiological hallmarks of HD, including spontaneous choreiform and dystonic movements, frontal-type cognitive deficits, and progressive heterogeneous striatal degeneration at least partially by apoptosis. 3NP produces the preferential degeneration of the medium-sized spiny GABAergic neurons with a relative sparing of interneurons and afferents, as was observed in HD striatum. The present manuscript reviews the different aspects of this neurotoxic treatment in rodents and non-human primates, and its interest as a phenotypic model of HD to understand the degenerative process of HD and test new therapeutic strategies.

Entities:  

Mesh:

Year:  1999        PMID: 10515664     DOI: 10.1016/s0301-0082(99)00005-2

Source DB:  PubMed          Journal:  Prog Neurobiol        ISSN: 0301-0082            Impact factor:   11.685


  104 in total

1.  Neuronal death enhanced by N-methyl-D-aspartate antagonists.

Authors:  C Ikonomidou; V Stefovska; L Turski
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-07       Impact factor: 11.205

2.  Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity.

Authors:  Ali Khoshnan; Jan Ko; Paul H Patterson
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-15       Impact factor: 11.205

3.  Differential electrophysiological changes in striatal output neurons in Huntington's disease.

Authors:  Véronique M André; Carlos Cepeda; Yvette E Fisher; My Huynh; Nora Bardakjian; Sumedha Singh; X William Yang; Michael S Levine
Journal:  J Neurosci       Date:  2011-01-26       Impact factor: 6.167

Review 4.  Excitotoxic and excitoprotective mechanisms: abundant targets for the prevention and treatment of neurodegenerative disorders.

Authors:  Mark P Mattson
Journal:  Neuromolecular Med       Date:  2003       Impact factor: 3.843

5.  pH as a biomarker of neurodegeneration in Huntington's disease: a translational rodent-human MRS study.

Authors:  Myriam M Chaumeil; Julien Valette; Céline Baligand; Emmanuel Brouillet; Philippe Hantraye; Gilles Bloch; Véronique Gaura; Amandine Rialland; Pierre Krystkowiak; Christophe Verny; Philippe Damier; Philippe Remy; Anne-Catherine Bachoud-Levi; Pierre Carlier; Vincent Lebon
Journal:  J Cereb Blood Flow Metab       Date:  2012-02-29       Impact factor: 6.200

Review 6.  Role of cell cycle re-entry in neurons: a common apoptotic mechanism of neuronal cell death.

Authors:  Jaume Folch; Felix Junyent; Ester Verdaguer; Carme Auladell; Javier G Pizarro; Carlos Beas-Zarate; Mercè Pallàs; Antoni Camins
Journal:  Neurotox Res       Date:  2011-10-01       Impact factor: 3.911

7.  Huntington's disease and mitochondrial alterations: emphasis on experimental models.

Authors:  Verónica Pérez-De la Cruz; Paul Carrillo-Mora; Abel Santamaría
Journal:  J Bioenerg Biomembr       Date:  2010-06       Impact factor: 2.945

8.  [18F]DPA-714 PET imaging of translocator protein TSPO (18 kDa) in the normal and excitotoxically-lesioned nonhuman primate brain.

Authors:  S Lavisse; K Inoue; C Jan; M A Peyronneau; F Petit; S Goutal; J Dauguet; M Guillermier; F Dollé; L Rbah-Vidal; N Van Camp; R Aron-Badin; P Remy; P Hantraye
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-12-09       Impact factor: 9.236

9.  Heat shock transcription factor-1 suppresses apoptotic cell death and ROS generation in 3-nitropropionic acid-stimulated striatal cells.

Authors:  Yong-Joon Choi; Ji-Yeon Om; Nam-Ho Kim; Ji-Eun Chang; Jun Ho Park; Ji-Young Kim; Hee Jae Lee; Sung-Soo Kim; Wanjoo Chun
Journal:  Mol Cell Biochem       Date:  2012-12-06       Impact factor: 3.396

10.  Metabonomic characterization of the 3-nitropropionic acid rat model of Huntington's disease.

Authors:  T M Tsang; J N Haselden; E Holmes
Journal:  Neurochem Res       Date:  2009-01-16       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.